Bellevue Life Sciences Acquisition Corp. Files 8-K

TL;DR

BLACU filed an 8-K on Oct 10, 2024, indicating a material agreement and financial obligations.

AI Summary

Bellevue Life Sciences Acquisition Corp. (BLACU) entered into a material definitive agreement on October 10, 2024. This filing also indicates the creation of a direct financial obligation or an off-balance sheet arrangement. The company is involved in the surgical and medical instruments and apparatus industry.

Why It Matters

This 8-K filing signals a significant event for Bellevue Life Sciences Acquisition Corp., potentially involving new financial obligations or agreements that could impact its future operations and financial standing.

Risk Assessment

Risk Level: medium — The filing of an 8-K detailing material definitive agreements and financial obligations suggests potential changes or commitments that could introduce financial risk or opportunity.

Key Players & Entities

• Bellevue Life Sciences Acquisition Corp. (company) — Filer of the 8-K report
• October 10, 2024 (date) — Date of the earliest event reported
• 3841 (industry_code) — Standard Industrial Classification for Surgical & Medical Instruments & Apparatus

FAQ

Key Financial Figures

• $0.0001 — ck Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Mar
• $11.50 — of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Ma
• $40,000 — sory Note ") in the principal amount of $40,000 to Jun Chul Whang, a member of the Comp
• $50,000 — 1. Other Events. On October 11, 2024, $50,000 was deposited in the trust account in c

Filing Documents

• d909034d8k.htm (8-K) — 31KB
• d909034dex101.htm (EX-10.1) — 19KB
• 0001193125-24-237600.txt ( ) — 236KB
• blacu-20241010.xsd (EX-101.SCH) — 5KB
• blacu-20241010_def.xml (EX-101.DEF) — 15KB
• blacu-20241010_lab.xml (EX-101.LAB) — 26KB
• blacu-20241010_pre.xml (EX-101.PRE) — 16KB
• d909034d8k_htm.xml (XML) — 9KB

From the Filing

8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. (Exact Name of Registrant as Specified in Charter) Delaware 001-41390 84-5052822 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 10900 NE 4th Street , Suite 2300 , Bellevue , WA 98004 (Address of Principal Executive Offices) (Zip Code) Registrant's telephone number, including area code ( 425 ) 635-7700 Not Applicable (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) Securities registered pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Units, each consisting of one share of common stock, one redeemable warrant and one right BLACU The Nasdaq Stock Market LLC Common stock, par value $0.0001 per share BLAC The Nasdaq Stock Market LLC Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share BLACW The Nasdaq Stock Market LLC Right to receive one-tenth (1/10) of one share of common stock BLACR The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (240.12b-2 of this chapter). Emerging growth company If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Item1.01. Entry into a Material Definitive Agreement. The information provided in Item 2.03 of this Current Report on Form 8-K is incorporated by reference into this Item 1.01. Item2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant. On October 10, 2024, Bellevue Life Sciences Acquisition Corp. (the " Company ") issued an unsecured promissory note (the " Promissory Note ") in the principal amount of $40,000 to Jun Chul Whang, a member of the Company's Board. The Promissory Note is not interest bearing and is payable in full on the earlier of: (i) November 9, 2024, (ii) at such time the Company raises additional working capital funds, or (iii) the date on which the Company consummates an initial business combination (the " Maturity Date "). In the event that the Company does not consummate a business combination on or prior to the time provided in the Company's Amended and Restated Certificate of Incorporation (as subject to extension), Mr. Whang agrees to forgive the principal balance of the Promissory Note, except to the extent of any funds remaining outside of the Company's trust account, if any. The following shall constitute an event of default: (i) a failure to pay the principal within five business days of the Maturity Date and (ii) the commencement of a voluntary or involuntary bankruptcy action. The foregoing description of the Promissory Note is qualified in its entirety by reference to the full text of the Promissory Note, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K and incorporated herein by reference. Item8.01. Other Events. On October 11, 2024, $50,000 was deposited in the trust account in connection with the extension of the date by which the Company must consummate a business combination. Item9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 Promissory Note, dated October 11, 2024, issued by Bellevue Life Sciences Acquisition Corp. to Jun Chul Whang 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: October 15, 2024 BELLEVUE LIFE SCIENCES ACQUISITION CORP. By: /s/ Kuk Hyoun Hwang Name: Kuk Hyoun Hwang Title: Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR